This metastatic allograft model serves as a highly relevant syngeneic representation of intraperitoneal high-grade serous TP53- and BRCA2-mutated ovarian carcinoma, suitable for evaluating PARPi (olaparib) efficacy [40]. Here, TP53 is linked to ovarian carcinoma.